Human lung adenocarcinoma-related monoclonal antibody and antigen and immunaossay method which uses the same

Abstract

The monoclonal antibody produced by a hybridoma cell strain TRD-L1, -L2 or -L3 which is obtained by the fusion between mouse myeloma cells and spleen cells of a mouse immunized with a human lung adenocarcinoma cell secretion component reacts in a specific fashion with a glycoprotein antigen that has a molecular weight of 200 kD or more (SDS-PAGE) and is present in human lung adenocarcinoma cells. It can be used efficiently in cancer diagnosis.

1 - 9 . (canceled)  
   
   
       10 . A monoclonal antibody or antigen binding fragment binding to a glycoprotein antigen which is produced from a human pulmonary adenocarcinoma cell and has a molecular weight of 200 kD or more determined by SDS-PAGE, the glycoprotein antigen reacting with PNA lectin and not reacting with GNA lectin, SNA lectin and DSA lectin.  
   
   
       11 . The monoclonal antibody or antigen binding fragment according to claim  1 , wherein a sugar chain terminal structure of the glycoprotein antigen has Gal (1-3) GalNAc structure and does not have Mannose, NeuAc (2-6) Gal and Gal (1-4) GlcNAc structures.  
   
   
       12 . The monoclonal antibody or antigen binding fragment according to claim  1 , wherein the antibody or fragment is of IgM isotype.  
   
   
       13 . The monoclonal antibody or antigen binding fragment according to claim  1 , wherein the antibody or fragment is a fragment selected from the group of a Fab, Fab(ab) 2  and a Fv fragment.  
   
   
       14 . The monoclonal antibody or antigen binding fragment according to claim  1 , wherein the antibody or fragment directly or indirectly is attached to a detectable label.  
   
   
       15 . An immunoassay method for diagnosis of human pulmonary adenocarcinoma, 
 the method comprising:    contacting a sample of a subject with a monoclonal antibody or antigen binding fragment binding to a glycoprotein antigen which is produced from the human pulmonary adenocarcinoma cell and has a molecular weight of 200 kD or more determined by SDS-PAGE, the glycoprotein antigen reacting with PNA lectin and not reacting with GNA lectin, SNA lectin and DSA lectin; and    measuring binding amount obtained on the basis of the contacting between the antibody or fragment and the glycoprotein antigen in the sample.    
   
   
       16 . The immunoassay method according to claim  6 , wherein a sugar chain terminal structure of the glycoprotein antigen has Gal (1-3) GalNAc structure and does not have Mannose, NeuAc (2-6) Gal and Gal (1-4) GlcNAc structures.  
   
   
       17 . The immunoassay method according to claim  6 , wherein the sample is human serum or human tissue.  
   
   
       18 . The immunoassay method according to claim  6 , wherein the antibody or fragment directly or indirectly is attached to a detectable label.  
   
   
       19 . The immunoassay method according to claim  6 , wherein the immunoassay method is a sandwich enzyme assay method.  
   
   
       20 . The immunoassay method according to claim  9 , wherein the label is an enzyme.